guest ::
| Home > Publications database > A masking clamp for conditional activation of therapeutic antibodies. |
| Home > Publications database > A masking clamp for conditional activation of therapeutic antibodies. |
| Journal Article | DKFZ-2025-02487 |
; ; ; ;
2025
Frontiers Media
Lausanne
Abstract: Therapeutic monoclonal antibodies (mAbs) constitute cornerstone therapeutics in oncology, yet their clinical utility is often limited by on-target, off-tumor toxicity due to shared antigen expression in both tumor and healthy tissues. To counteract this issue, various approaches, including pH-dependent, as well as affinity-based and steric hindrance-based masked antibodies, have been developed. Several steric hindrance-based masking strategies have been proposed utilizing non-human proteins, potentially leading to an immunogenic response. To address this challenge, we engineered a modular protein-based masking platform leveraging the high-affinity interaction between human calmodulin (CaM) and a calmodulin-binding peptide (CBP). This strategy enables conditional activation of antibodies via tumor microenvironment (TME)-associated proteases (e.g., MMP-9), minimizing systemic off-tumor binding. The CaM-CBP peptide clamp, composed exclusively of human-derived protein domains, was fused to the amino termini of heavy and light chains of trastuzumab and cetuximab. On-cell binding assays demonstrated up to a 410-fold reduction in EC50 for masked constructs across multiple antigen-antibody systems. Functional validation using a reporter-cell-based antibody-dependent cellular cytotoxicity (ADCC) assay confirmed that masking abrogated effector cell activation, leading to up to 78-fold reduction of EC50 and no ADCC activation at concentrations corresponding to the onset of maximal ADCC activation by unmodified antibodies. Demasking via MMP-9-mediated linker hydrolysis restored antigen binding and ADCC potency. Structural optimization revealed that linker length and clamp positioning critically influenced masking efficiency. This human-derived, modular masking platform mitigates immunogenicity risks while enabling tumor-selective antibody activation. Its adaptability across antibody scaffolds underscores broad applicability for improving the therapeutic index of antibodies.
Keyword(s): Humans (MeSH) ; Trastuzumab: immunology (MeSH) ; Trastuzumab: pharmacology (MeSH) ; Trastuzumab: genetics (MeSH) ; Calmodulin: metabolism (MeSH) ; Calmodulin: immunology (MeSH) ; Calmodulin: genetics (MeSH) ; Calmodulin: chemistry (MeSH) ; Tumor Microenvironment: immunology (MeSH) ; Cetuximab: immunology (MeSH) ; Cetuximab: pharmacology (MeSH) ; Cetuximab: genetics (MeSH) ; Cell Line, Tumor (MeSH) ; Matrix Metalloproteinase 9: metabolism (MeSH) ; Antineoplastic Agents, Immunological: pharmacology (MeSH) ; Antibodies, Monoclonal: immunology (MeSH) ; MMP-9 ; antibody engineering ; antibody masking ; conditional antibody activation ; off-target toxicity ; Trastuzumab ; Calmodulin ; Cetuximab ; Matrix Metalloproteinase 9 ; Antineoplastic Agents, Immunological ; Antibodies, Monoclonal
; 
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
